Environmental enrichment reverses ELS-induced visceral pain and depression through a prefrontal-limbic circuit involving CB1Rs
- Commun Biol. 2026 Apr 24;9(1):871. doi: 10.1038/s42003-026-10105-2.
- 1. Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, China.
- 2. Jiangsu Province Key Laboratory of Anesthesiology and Brain Science, Xuzhou Medical University, Xuzhou, China.
- 3. The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou No.1 People's Hospital, Xuzhou, China.
- 4. Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, China. [email protected].
- 5. Jiangsu Province Key Laboratory of Anesthesiology and Brain Science, Xuzhou Medical University, Xuzhou, China. [email protected].
- # Contributed equally.
Neonatal colorectal distension (CRD), as a mechanical stress stimulus in early life to simulate irritable bowel syndrome (IBS), increases susceptibility to visceral pain and depression-like behaviors in adulthood. Enriched environment (EE) treatment effectively counteracts these effects, but the underlying neural circuit and molecular mechanisms remain poorly defined. Here, we investigate whether EE reverses visceral pain and depression by modulating cannabinoid type-1 receptors (CB1Rs) in the PrLGlu→avBNST pathway. A multidisciplinary combination of behaviors, chemogenetics, optogenetics, pharmacology, molecular and electrophysiological approaches is applied. In CRD rats, CB1Rs-expressing glutamatergic neurons in prelimbic cortex (PrL) projecting to the anteroventral bed nucleus of the stria terminalis (avBNST) promote visceral pain and depression. EE exerts analgesic and antidepressant effects by rescuing PrLGlu→avBNSTGABA pathway activity and reducing CB1Rs expression. EE also reverses the CRD-induced paraventricular nucleus (PVN) hyperactivity by reversing the dysfunction of this pathway. Together, EE alleviates chronic visceral pain and comorbid depression by restoring homeostasis in the CB1Rs-modulated PrLGlu→avBNSTGABA→PVN pathway. Combining EE and CB1Rs-targeted pharmacological modulation offers a promising therapeutic strategy for early-life developmental disorder-related pain-depression comorbidities.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Neurological Disease
-
Research Areas: Neurological Disease
-
target: iGluRResearch Areas: Neurological Disease
-
target: Cannabinoid ReceptorResearch Areas: Others